���构特征与受体作用机制 — Research Overview

By Editorial Desk · published 2025-10-30 · last reviewed 2025-12-08 · Blog

A practical reference on deamidation: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2025-12-08 and is reviewed periodically as new material appears.

结构特征与受体作用机制

皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。

序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。

Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。

Storage Stability and Analytical Control

As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.

Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.

Semaglutide at a glance

Handling, Storage, and Analytical Verification

Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.

Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.

Related pages on this site

• Efficient dataset
• Portable update
• Scalable notes
• Sustainable trends
• Professional report
• Modular index
• Technical collection
• Scheduled comparison

Storage, Stability, and Analytical Control

Degradation proceeds along several parallel routes. Deamidation of asparagine and glutamine residues generates charged variants that shift retention time in chromatographic analysis. Oxidation targets methionine and can be accelerated by trace metals or dissolved oxygen. Non-covalent aggregation produces dimers, oligomers, and larger species that are difficult to reverse. Isomerisation at aspartate residues is slower but measurable under thermal stress. The distribution among these pathways depends on pH, buffer composition, ionic strength, and the presence of excipients such as sugars or surfactants.

Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nm is the standard purity method, reported as area percent. Mass spectrometry, usually with electrospray ionisation, confirms identity and reveals covalent modifications. Size-exclusion chromatography quantifies aggregates and fragments. Peptide mapping after enzymatic digestion localises changes to specific sequence regions. Circular dichroism and infrared spectroscopy report on secondary structure, while light scattering tracks particle formation in liquid formulations. No single technique captures every quality attribute.

Quality control relies on pharmacopoeial monographs where they exist, combined with in-house specifications for identity, purity, water content, and counter-ion composition. Reference standards allow calibration across laboratories, although certified materials for every analogue are not universally obtainable. Batch records, chromatograms, and mass spectra form the documentation trail. Regulatory classification varies by jurisdiction and intended use, and research-grade material differs from pharmaceutical-grade material in testing scope. Analytical uncertainty is often expressed as relative standard deviation across replicate injections.

Background and Molecular Profile

Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.

Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.

The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.

Background from the literature

In the March 2005 issue of Science, Mary Higby Schweitzer of North Carolina State University and colleagues announced the recovery of soft tissue from the marrow cavity of a fossilized leg bone from a T. rex. The bone had been intentionally, though reluctantly, broken for shipping and then not preserved in the normal manner, specifically because Schweitzer was hoping to test it for soft tissue. Designated as the Museum of the Rockies specimen 1125, or MOR 1125, the dinosaur was previously excavated from the Hell Creek Formation. Flexible, bifurcating blood vessels and fibrous but elastic bone matrix tissue were recognized. In addition, microstructures resembling blood cells were found inside the matrix and vessels. The structures bear resemblance to ostrich blood cells and vessels. Whether an unknown process, distinct from normal fossilization, preserved the material, or the material is original, the researchers do not know, and they are careful not to make any claims about preservation. If it is found to be original material, any surviving proteins may be used as a means of indirectly guessing some of the DNA content of the dinosaurs involved, because each protein is typically created by a specific gene. The absence of previous finds may be the result of people assuming preserved tissue was impossible, therefore not looking. Since the first, two more tyrannosaurs and a hadrosaur have also been found to have such tissue-like structures. Research on some of the tissues involved has suggested that birds are closer relatives to tyrannosaurs than other modern animals.

== Work history == While researching at Case Western Reserve, Tippett moonlighted as an emergency room physician and instructor in Emergency and Outpatient Medicine. He spent much of his early clinical career (1989–1995) in Emergency Medicine in Ohio and California. He received his board certification in Internal Medicine in 1987. Between 1993 and 2000, he served on the board of the Computer Ethics Institute. He served as executive director of The Pacific Foundation for Science and Medicine from 1988 to 1992, an intersection of his clinical career with an emerging focus on technology, particularly cybersecurity, and the use and access protocols of the Internet. It was in his role as president and chairman of Certus International, a publisher and developer of PC anti-virus and security software, that Tippett applied his research insights as a biochemist to the concept of computer "viruses" to develop the anti-virus software, "Vaccine," which was later purchased by Symantec in 1992. His CEO role with Cybertrust led to a merger of Cybertrust by Verizon, and Tippett's role in the Verizon healthcare and security innovations divisions. Tippett served as chairman of the Alliance for Internet Security in 2000. He represented Verizon on the board of directors of The Open Identity Exchange (OIX) and the Information Card Foundation.

=== Phase II === Study 980231 (Randomized, double-blind, placebo-controlled). Three dose regimens were included: "pre-post", "pre", and placebo Palifermin administration (60 micrograms/kg) by IV for three consecutive days before chemotherapy and after autologous peripheral blood progenitor cell (PBPC). Efficacy was demonstrated in the drug versus the placebo.

Sources: en.wikipedia.org

Reference notes

In cell biology, cell fractionation is the process used to separate cellular components while preserving individual functions of each component. This is a method that was originally used to demonstrate the cellular location of various biochemical processes. Other uses of subcellular fractionation is to provide an enriched source of a protein for further purification, and facilitate the diagnosis of various disease states.

== Early life == Charles Herbert Best was born in Pembroke, Maine, on February 27, 1899, to Luella (Lulu) Fisher and Herbert Huestis Best, a Canadian-born physician from Nova Scotia. His father, Herbert Best, was a doctor in a small Maine town with a limited economy based mostly on sardine-packing. His mother Lulu was a soprano singer, organist, and pianist. Charles Best grew up in Pembroke before going to Toronto, Ontario, to study medicine in 1915. By the time Best had reached college age and was choosing between such schools as McGill University and the University of Toronto, family connections persuaded him to pursue his studies in Toronto. Family illness had guided Best's research interests—his Aunt Anna dying of diabetes had profound effects on him. It was for this reason, and the fact that his father was a physician, that he chose to study at University of Toronto and train to become a doctor. His university studies were interrupted following his first year by the onset of the First World War. He served as an infantry soldier, reaching the rank of acting Sergeant Major. Following his service, he eventually returned to university in Toronto, but was falling behind in his classes.

A precarious number of people managed to return to responsible work, while at the other extreme, people were left with severe and disabling impairments. Most people fell into an intermediate group, left with some improvement of their symptoms but also with emotional and intellectual deficits to which they made a better or worse adjustment. On average, there was a mortality rate of approximately 5% during the 1940s. A survey of British lobotomy patients lobotomised between 1942 and 1954 found that 13% of patients were deemed to have made a full recovery and a further 28% were deemed to have made a significant recovery; for 25% lobotomy was deemed to have made no change and 4% died as a result of the surgery. Patients after lobotomy can have a lowering and stabilising of blood pressure. They may have inertia, struggle to complete test problems, and might suffer from metabolic disorders. They may also be considered dispassionate about their feelings because they lack a strong emotional component. It is reported that the patients face less anxiety and stress, but have a constant feel of depression. The frontal lobotomy procedure could have severe negative effects on a patient's personality and ability to function independently. Lobotomy patients often show a marked reduction in initiative and inhibition. They may also exhibit difficulty imagining themselves in the position of others because of decreased cognition and detachment from society. Walter Freeman coined the term "surgically induced childhood" and used it constantly to refer to the results of lobotomy.

Research is underway to use nanomaterials for purposes including more efficient solar cells, practical fuel cells, and environmentally friendly batteries. The most advanced nanotechnology projects related to energy are: storage, conversion, manufacturing improvements by reducing materials and process rates, energy saving (by better thermal insulation for example), and enhanced renewable energy sources. One major project that is being worked on is the development of nanotechnology in solar cells. Solar cells are more efficient as they get tinier and solar energy is a renewable resource. The price per watt of solar energy is lower than one dollar. Research is ongoing to use nanowires and other nanostructured materials with the hope of to create cheaper and more efficient solar cells than are possible with conventional planar silicon solar cells. Another example is the use of fuel cells powered by hydrogen, potentially using a catalyst consisting of carbon supported noble metal particles with diameters of 1–5 nm. Materials with small nanosized pores may be suitable for hydrogen storage. Nanotechnology may also find applications in batteries, where the use of nanomaterials may enable batteries with higher energy content or supercapacitors with a higher rate of recharging. Nanotechnology is already used to provide improved performance coatings for photovoltaic (PV) and solar thermal panels. Hydrophobic and self-cleaning properties combine to create more efficient solar panels, especially during inclement weather.

Sources: en.wikipedia.org

Frequently asked questions